Exicure, Inc. (XCUR): Total Liabilities
$10.12M
As of 2025-12-31
$10.42M
As of 2026-06-30
+6.4%
3-year compound annual growth
-23.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.12M | +22.1% | 2026-03-25, Balance as of period end |
| 2024-12-31 | $8.28M | -3.1% | 2026-03-25, Balance as of period end |
| 2023-12-31 | $8.55M | +1.7% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $8.41M | -84.3% | 2024-06-06, Balance as of period end |
| 2021-12-31 | $53.64M | +37.7% | 2023-03-27, Balance as of period end |
| 2020-12-31 | $38.94M | +12.8% | 2022-03-25, Balance as of period end |
| 2019-12-31 | $34.52M | +342.3% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $7.80M | -13.4% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $9.01M | n/c | 2019-09-23, Balance as of period end |
| 2016-12-31 | $18.13M | n/a | 2018-03-09, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Exicure, Inc. (XCUR) | 2025-12-31 | $10.12M | +22.1% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare XCUR, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗